Jeffrey Axler

3.4k total citations · 1 hit paper
16 papers, 2.4k citations indexed

About

Jeffrey Axler is a scholar working on Epidemiology, Genetics and Gastroenterology. According to data from OpenAlex, Jeffrey Axler has authored 16 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Epidemiology, 13 papers in Genetics and 7 papers in Gastroenterology. Recurrent topics in Jeffrey Axler's work include Inflammatory Bowel Disease (13 papers), Microscopic Colitis (11 papers) and Celiac Disease Research and Management (5 papers). Jeffrey Axler is often cited by papers focused on Inflammatory Bowel Disease (13 papers), Microscopic Colitis (11 papers) and Celiac Disease Research and Management (5 papers). Jeffrey Axler collaborates with scholars based in United States, Canada and United Kingdom. Jeffrey Axler's co-authors include William J. Sandborn, Brian G. Feagan, Silvio Danese, Irving H. Fox, Stephen B. Hanauer, Catherine Milch, Serap Sankoh, Tim Wyant, Asit Parikh and Paul Rutgeerts and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and American Journal of Clinical Nutrition.

In The Last Decade

Jeffrey Axler

15 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

2013 2.0k citations Brian G. Feagan, Paul Rutgeerts et al. New England Journal of Medicine profile →

Peers

Jeffrey Axler

GENET

EPIDE

IMMUN

SURGE

GASTR

Brihad Abhyankar United States

Stephan Targan United States

Wojciech Niezychowski United States

Pál Miheller Hungary

M. Vilien Denmark

Per Karlén Sweden

Paul J. Healey United States

Erik Hertervig Sweden

Edyta Zagórowicz Poland

Omoniyi J. Adedokun United States

Brihad Abhyankar United States

Jeffrey Axler

1.8k ×0.9

GENET

1.4k ×0.9

EPIDE

585 ×0.8

IMMUN

543 ×1.0

SURGE

171 ×0.8

GASTR

Citations per year, relative to Jeffrey Axler Jeffrey Axler (= 1×) peers Brihad Abhyankar

Countries citing papers authored by Jeffrey Axler

Since Specialization

Citations

This map shows the geographic impact of Jeffrey Axler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Axler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Axler more than expected).

Fields of papers citing papers by Jeffrey Axler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Axler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Axler. The network helps show where Jeffrey Axler may publish in the future.

Co-authorship network of co-authors of Jeffrey Axler

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Axler. A scholar is included among the top collaborators of Jeffrey Axler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Axler. Jeffrey Axler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Ferrante, Marc, Peter M. Irving, María T. Abreu, et al.. (2023). Maintenance Risankizumab Sustains Induction Response in Patients with Crohn’s Disease in a Randomized Phase 3 Trial. Journal of Crohn s and Colitis. 18(3). 416–423. 5 indexed citations

Irving, Peter M., María T. Abreu, Jeffrey Axler, et al.. (2022). DOP84 Risankizumab maintenance therapy results in sustained improvements in endoscopic outcomes in patients with moderate to severe Crohn’s Disease: Post-hoc analysis from the phase 3 study FORTIFY. Journal of Crohn s and Colitis. 16(Supplement_1). i127–i128. 3 indexed citations

Sutcliffe, Simon, Shirin Kalyan, Darby Thompson, et al.. (2019). Novel Microbial-Based Immunotherapy Approach for Crohn's Disease. Frontiers in Medicine. 6. 170–170. 5 indexed citations

Feagan, Brian G., Stefan Schreiber, Douglas C. Wolf, et al.. (2018). Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis. Inflammatory Bowel Diseases. 25(6). 1028–1035. 21 indexed citations

Yajnik, Vijay, Nabeel Khan, Marla C. Dubinsky, et al.. (2017). Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age. Advances in Therapy. 34(2). 542–559. 68 indexed citations

Stallmach, Andreas, Bernd Bokemeyer, Jeffrey Axler, et al.. (2017). DOP026 Sustained remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis of week 14 remitters. Journal of Crohn s and Colitis. 11(suppl_1). S42–S43. 1 indexed citations

Rubin, David T., Russell D. Cohen, William J. Sandborn, et al.. (2017). Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. Journal of Crohn s and Colitis. 11(7). 785–791. 55 indexed citations

Rubin, David T., Russell D. Cohen, William J. Sandborn, et al.. (2015). OP011. Budesonide MMX(R) 9 mg for Inducing Remission in Patients with Mild-to-Moderate Ulcerative Colitis Not Adequately Controlled with Oral 5-ASAs. Journal of Crohn s and Colitis. 9(suppl 1). S7–S7. 7 indexed citations

Erzın, Yusuf, Nurhan Demir, Fatih Kantarcı, et al.. (2015). P565. The Increased Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients is not Related To Inflammatory Load. Journal of Crohn s and Colitis. 9(suppl 1). S363–S363. 3 indexed citations

10.

Erzın, Yusuf, Nurhan Demir, Fatih Kantarcı, et al.. (2015). P566. Efficacy and safety of vedolizumab with advancing age in patients with ulcerative colitis: Results from the GEMINI 1 study. Journal of Crohn s and Colitis. 9(suppl 1). S363–S364. 1 indexed citations

11.

Yajnik, Vijay, Nabeel Khan, Marla C. Dubinsky, et al.. (2015). Sa1274 Efficacy and Safety of Vedolizumab With Advancing Age in Patients With Ulcerative Colitis: Results From the GEMINI 1 Study. Gastroenterology. 148(4). S–278. 5 indexed citations

12.

Feagan, Brian G., Paul Rutgeerts, Bruce E. Sands, et al.. (2013). Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine. 369(8). 699–710. 2048 indexed citations breakdown →

13.

Feagan, Brian G., Paul Rutgeerts, Bruce E. Sands, et al.. (2012). Vedolizumab Maintenance Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial. The American Journal of Gastroenterology. 107. S609–S610. 12 indexed citations

14.

Feagan, Brian G., P. J. Rutgeerts, B E Sands, et al.. (2012). 943b Induction Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial. Gastroenterology. 142(5). S–160. 31 indexed citations

15.

O'Brien, Paul, et al.. (1999). Multiple Familial Gastrointestinal Autonomic Nerve Tumors and Small Intestinal Neuronal Dysplasia. The American Journal of Surgical Pathology. 23(2). 198–204. 48 indexed citations

16.

Lemoyne, Michel, et al.. (1987). Breath pentane analysis as an index of lipid peroxidation: a functional test of vitamin E status. American Journal of Clinical Nutrition. 46(2). 267–272. 106 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact